---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-016589"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2025-06-26T23:59:59+00:00"
generated_at: "2026-05-18T17:48:44.633144+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lipocine doses first patient in Phase 3 trial for oral brexanolone (LPCN 1154) in postpartum depression

## Summary
- First patient dosed in pivotal Phase 3 trial of LPCN 1154 (oral brexanolone) for postpartum depression; top line data expected Q2 2026.
- Trial is outpatient with no medical monitoring required; 48-hour treatment regimen, randomized, blinded vs placebo in women ≥15 with severe PPD.
- Primary endpoint is change from baseline in HAM-D scale; NDA submission targeted for mid-2026 based on Phase 3 data.
- Virtual investor event on LPCN 1154 scheduled for July 9, 2025 at 11:00 AM ET.

## SEC filing metadata
- accession: 0001641172-25-016589
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2025-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000164117225016589/0001641172-25-016589-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000164117225016589/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-016589
- JSON: https://secwatch.observer/filing/0001641172-25-016589.json
- Plain text: https://secwatch.observer/filing/0001641172-25-016589.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.